HIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
|
|
- Adam Ethelbert Whitehead
- 6 years ago
- Views:
Transcription
1 HIV Update 2014 Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
2 Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections in 2011 Deaths due to AIDS in million [2.2 million 2.8 million] 1.7 million [1.5 million 1.9 million]
3 The Global Picture (2011) On ART: 8 million Number needing ART: 15 million New infections: 2 million People were waiting to become treatment-eligible, sicken, or die: ~24 million Estimated coverage of ART in low- and middle-income countries: 36% Granich R, et al. Curr Opin HIV AIDS. 2013;8:41-49.
4 No Single, Stand-Alone HIV Prevention Intervention Will Halt the HIV Pandemic Over the past 30 years, existing prevention strategies have had limited to no success Education about risks Behavioral interventions to decrease risk Harm reduction Circumcision ART Vaccines
5 Simultaneous Use of Different Classes of Prevention Strategies
6 Potential Therapeutic Targets CCR5 Inhibitors Fusion Inhibitors Cytoplasm Reverse Transcriptase Inhibitors Protease Inhibitors Integrase Inhibitors Nucleus
7 HIV Attachment, Co-receptor Binding, and Fusion Targets for Inhibition CD4 Attachment Co-receptor Binding Virus Cell Fusion CD4 attachment inhibitors gp41 gp120 CCR5 antagonists Fusion inhibitors V3 loop CD4 Cell membrane CCR5 or CXCR4 Adapted from Moore JP, et al. Proc Natl Acad Sci USA 2003;100:
8 When to Start Treatment Clinical Category AIDS-defining illness or severe symptoms CD4 Count (cells/mm 3 ) HIV RNA (copies/ml) 2/2013 DHHS Guidelines Any value Any value Treat 2012 IAS-USA Guidelines Asymptomatic <500 Any value Treat >500 Any value Treat Pregnant women Any value Any value Treat HIV-associated nephropathy Any value Any value Treat HIV/HBV coinfection when HBV treatment is indicated Any value Any value Treat The IAS-USA guidelines also recommends initiating antiretroviral therapy in HIV-infected patients with active hepatitis C virus infection, active or high risk for cardiovascular disease, and symptomatic primary HIV infection. DHHS. Available at: Revision February 12, 2013; Thompson MA, et al. JAMA. 2012;308:
9 CIPRA HT 001
10 Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti with a CD4 Count of cells/mm 3 Study Features N = 816 persons enrolled 18 years of age or older Randomized, open label, controlled Conducted in Haiti Antiretroviral naïve CD4 count: cells/mm 3 HIV RNA > 10,000 copies/ml Absence of AIDS diagnosis Early-Treatment Group (initiated *antiretroviral therapy within 2 weeks after enrollment) (n = 408) Standard-Treatment Group (initiated *antiretroviral therapy when single CD4 < 200 cells/mm 3 or when AIDS-defining illness) (n = 408) *Antiretroviral therapy = zidovudine + lamivudine + efavirenz Source: Severe P, et al. N Eng J Med 2010; 363:
11 Probability of Survival Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti with a CD4 T cell count of cells/mm 3 Kaplan Meier Estimates of Survival in Treatment Groups 1.00 Early antiretroviral treatment P=0.001 Standard antiretroviral treatment No. at Risk Early treatment 408 Standard treatment Source: Severe P, et al. N Eng J Med 2010; 363: Months
12 ANTIRETROVIRAL THERAPY Strategic Timing of Antiretroviral Therapy (START) Randomized Controlled Trial: INSIGHT* START 001 Study Features CD4 count >500 cells/mm 3 N = 4,000 planned persons enrolled N = 900 for pilot phase Age 18 years of age or older Randomized, open label, controlled Antiretroviral naïve Absence of AIDS diagnosis Setting: 22 countries Early Antiretroviral Therapy (initiate antiretroviral therapy immediately after enrollment) Deferred Antiretroviral Therapy (initiate antiretroviral therapy when two values of CD4 < 350 cells/mm 3 or AIDS develops) *INSIGHT = International Network for Strategic Initiatives in Global HIV Trials Source:
13 Newer ART regimens The Shift Towards Earlier Initiation of Antiretroviral Therapy - Generally better tolerated, more convenient, and more potent than older regimens Survival benefit - Randomized controlled trials - Observational cohort data Untreated HIV - Maybe associated with the development of non-aids-defining illness Biologic rationale Effective ART reduces HIV transmission
14 Summary and Implications New ARV Guidelines Recommendations for earlier initiation Guideline have major influence on clinical practice
15 DHHS and IAS-USA Guidelines: What to Start DHHS Preferred Regimens [1] IAS-USA Recommended Regimens [2] NNRTI Boosted PI EFV/TDF/FTC ATV/RTV + TDF/FTC DRV/RTV + TDF/FTC EFV/TDF/FTC or EFV + ABC/3TC* INSTI RAL + TDF/FTC RAL + TDF/FTC ATV/RTV + (TDF/FTC or ABC/3TC* ) DRV/RTV + TDF/FTC DHHS Alternative Regimens [1] IAS-USA Alternative Regimens [2] NNRTI Boosted PI based INSTI based EFV + ABC/3TC* RPV/TDF/FTC or RPV + ABC/3TC* ATV/RTV + ABC/3TC DRV/RTV + ABC/3TC FPV/RTV + (TDF/FTC or ABC/3TC) LPV/RTV + (TDF/FTC or ABC/3TC ) RAL + ABC/3TC* EVG/COBI/TDF/FTC NVP + (TDF/FTC or ABC/3TC* ) RPV/TDF/FTC or RPV + ABC/3TC* DRV/RTV + ABC/3TC LPV/RTV + (TDF/FTC or ABC/3TC* ) RAL + ABC/3TC* EVG/COBI/TDF/FTC *In HLA-B*5701 negative patients with baseline HIV-1 RNA < 100,000 copies/ml. Avoiding the use of ABC or LPV/RTV might be considered for patients with or at high risk of cardiovascular disease. 1. DHHS Guidelines. February Thompson MA, et al. JAMA. 2012;308:
16 DHHS Guidelines: October 2013 Update on Integrase Inhibitors NNRTI Boosted PI INSTI Preferred Regimens EFV/TDF/FTC ATV/RTV + TDF/FTC DRV/RTV + TDF/FTC RAL + TDF/FTC EVG/COBI/TDF/FTC DTG + ABC/3TC DTG + TDF/FTC Alternative Regimens EFV + ABC/3TC RPV/TDF/FTC or RPV + ABC/3TC ATV/RTV + ABC/3TC DRV/RTV + ABC/3TC FPV/RTV + (TDF/FTC or ABC/3TC) LPV/RTV + (TDF/FTC or ABC/3TC) RAL + ABC/3TC All 3 integrase inhibitors are now part of preferred first-line regimens DHHS Guidelines, February DHHS Recommendation on INSTIs, October 2013.
17 2013 Update: EACS Guidelines for Treatment of HIV-Infected Pts in Europe Recommendation for ART initiation remains at CD4+ cell counts < 350 cells/mm 3 ART can be considered at higher CD4+ counts, depending on patient readiness Guideline AIDS or HIV-Related Symptoms CD4+ Cell Count < > 500 EACS [1] Yes Yes Consider Consider US DHHS [2] Yes Yes Yes Yes IAS-USA [3] Yes Yes Yes Yes WHO [4] Yes Yes Yes Not addressed* *ART may be recommended for the HIV+ partner in serodiscordant couples as prevention of transmission. 1. EACS Guidelines, February DHHS Guidelines, February IAS-USA Guidelines, July WHO ART Guidelines, June 2013.
18 Factors to Consider in Choosing First-line Therapy Patient s willingness to commit to therapy/concerns regarding adherence Baseline characteristics (eg, CD4+ cell count, HIV-1 RNA, resistance) Efficacy data Tolerability Convenience Drug drug or drug food interactions Comorbid conditions (eg, HBV, CV risk, renal, bone) Consequences of failure (resistance) Since the introduction of potent ARV therapy, preferred regimens all include 2 NRTIs + third drug
19 Readiness for Therapy: A Key Decision Point Potential options PI-based therapy: lower risk of resistance at treatment failure with boosted PIs vs NNRTI- and RAL-based strategies Simple regimen (1 pill, once daily): adherence more likely Regimens to avoid Complicated regimens: frequent dosing, food requirements Regimens with more adverse events: may affect adherence Regimens with higher risk of resistance at failure
20 Selection of NRTIs for First-line Therapy
21 ACTG 5202: First-line Therapy With ABC/3TC vs TDF/FTC + EFV vs ATV/RTV Stratified by HIV-1 RNA < or 100,000 copies/ml Wk 96 TDF/FTC* 300/200 mg QD + EFV 600 mg QD (n = 464) Antiretroviral-naive patients with HIV-1 RNA 1000 copies/ml and any CD4+ cell count (N = 1857) *Double blind. Open label. ABC/3TC* 600/300 mg QD + EFV 600 mg QD (n = 465) TDF/FTC* 300/200 QD + ATV/RTV 300/100 mg QD (n = 465) ABC/3TC* 600/300 mg QD + ATV/RTV 300/100 mg QD (n = 463) Sax PE, et al. N Engl J Med. 2009;361: Daar ES, et al. Ann Intern Med. 2011;154:
22 Probability of No Virologic Failure (%) A5202: Time to Virologic Failure in Patients With HIV-1 RNA 100,000 c/ml HR: 2.33 (95% CI: ; P <.001, log-rank test) TDF/FTC (26 events) ABC/3TC (57 events) Pts at Risk, n ABC/3TC TDF/FTC Sax PE, et al. N Engl J Med. 2009;361: Wks Since Randomization
23 Probability (Remaining Free of Virologic Failure) A5202: Time to Virologic Failure in Patients With HIV-1 RNA < 100,000 c/ml EFV + TDF/FTC (33 events) EFV + ABC/3TC (39 events) ATV/RTV + TDF/FTC (29 events) ATV/RTV + ABC/3TC (35 events) Pts at Risk, n EFV + TDF/FTC EFV + ABC/3TC ATV/RTV + TDF/FTC ATV/RTV + ABC/3TC Wks From Randomization Sax PE, et al. J Infect Dis. 2011:204;
24 HIV-1 RNA < 50 c/ml at Wk 48 (%) SINGLE Study: First-line Therapy With Dolutegravir/ABC/3TC vs EFV/TDF/FTC Difference (%): +7.4 (+2.5, +12.3; P =.003) DTG noninferior and superior to EFV at Wk 48 primary efficacy endpoint Time to HIV-1 RNA < 50 copies/ml days with DTG vs 84 days with EFV (P <.0001) 20 0 DTG 50 mg + ABC/3TC QD (n = 414) EFV/TDF/ FTC QD (n = 419) CD4+ cell change +267 with DTG vs +208 with EFV (P <.001) Walmsley S, et al. ICAAC Abstract H-556b.
25 Dolutegravir Effective With ABC/3TC or TDF/FTC, Regardless of BL HIV-1 RNA HIV-1 RNA < 50 c/ml at Wk 48 by Subgroup (FDA Snapshot Analysis), % BL HIV-1 RNA 100,000 c/ml ABC/3TC TDF/FTC BL HIV-1 RNA > 100,000 c/ml ABC/3TC TDF/FTC DTG + NRTIs SPRING-2 RAL + NRTIs DTG + ABC/3TC SINGLE EFV/TDF/ FTC DTG well tolerated with similar renal safety with either ABC/3TC or TDF/FTC Eron J, et al. Glasgow Abstract P204.
26 Concerns Regarding NRTIs ABC TDF Decreased potency compared with TDF in those with high HIV-1 RNA levels (> 100,000 copies/ml) when combined with EFV and ATV + RTV Variable results regarding relationship with CV events Avoid in patients with positive HLA-B*5701 test Associated with greater decline in bone mineral density than ABC Associated with variable decline in renal function compared with other NRTIs
27 Selecting the Third Drug in a First-line Regimen
28 What s Available as Fixed-Dose Combinations, and What s Coming? Available Now Efavirenz/tenofovir DF/ emtricitabine Rilpivirine/tenofovir DF/ emtricitabine Elvitegravir/cobicistat/ tenofovir DF/emtricitabine Future Options Darunavir/cobicistat Darunavir/cobicistat/ emtricitabine/tenofovir alafenamide (GS- 7340) Atazanavir/cobicistat Dolutegravir/abacavir/ lamivudine Dolutegravir will be initially available as single tablet, not fixed-
29 HIV-1 RNA < 50 c/ml (%) HIV-1 RNA < 50 c/ml (%) Efficacy Comparison of Boosted PIs 100 ARTEMIS [1] (ITT, TLOVR) 96 Wks 100 CASTLE [2] (ITT, NC = F) 96 Wks LPV/RTV 800/200 QD or BID 343 DRV/RTV 800/100 QD 1. Mills A, et al. AIDS. 2009;23: Molina JM, et al. J Acquir Immune Defic Syndr. 2010;53: LPV/RTV 400/100 BID ATV/RTV 300/100 QD
30 Probability (Remaining Free of Virologic Failure) A5202: Efficacy With ATV/RTV vs EFV Pts at Risk, n 0 EFV + TDF/FTC EFV + ABC/3TC ATV/RTV + TDF/FTC ATV/RTV + ABC/3TC EFV + TDF/FTC (57 events) EFV + ABC/3TC (72 events) ATV/RTV + TDF/FTC (57 events) ATV/RTV + ABC/3TC (83 events) Wks From Randomization Daar ES, et al. Ann Intern Med. 2011;154: Sax PE, et al. J Infect Dis. 2011;204:
31 HIV-1 RNA < 50 c/ml (%) STARTMRK: Efficacy of RAL vs EFV RAL is BID vs QD (EFV) but fewer adverse events (52% vs 80%) CD4+ gain: ITT, NC = F Pts at Risk, n RAL 400 mg BID EFV 600 mg QHS Wks Rockstroh JK, et al. J Acquir Immune Dis Syndr. 2013;63:77-85.
32 ECHO and THRIVE: HIV-1 RNA < 50 c/ml With EFV vs RPV ECHO Wk 48 Wk 96 Favors EFV -3.2% -0.4% Favors RPV P =.0055 P <.0001 THRIVE Wk 48 Wk % 2.4% P <.0001 P <.0001 Pooled Wk % P <.0001 ITT-TLOVR Percent Difference (Noninferiority at 12% Margin) Cohen CJ, et al. AIDS. 2013;27: Molina JM, et al. Lancet. 2011;378: Cohen CJ, et al. Lancet. 2011;378: All patients received TDF/FTC.
33 Investigational Rilpivirine (formerly TMC-278) Rilpivirine-3D Structure NNRTI compound with potent activity Once daily dose: 25 mg Planned co-formulation with Tenofovir-Emtricitabine Less CNS disturbances than efavirenz and non-teratogenic From: Azijn H, et al. AAC. 2010:54; Active against most nevirapine and efavirenz-resistant clinical isolates Unfavorable interactions with acid suppressant medications From: Garvey L, et al. Expert Opin Investig Drugs. 2009;18:
34 Investigational Rilpivirine (TMC-278) vs. Efavirenz in ARV-Naive ECHO and THRIVE: Results 48 Week Data: Virologic Response ( ITT-TLOVR) All regimens included 2 NRTIs Source: Cohen C, et al. 17 th International AIDS Conference. 2010:THLBB206.
35 Investigational Rilpivirine (TMC-278) vs. Efavirenz in ARV-Naive ECHO and THRIVE: Results 48 Week Data: Virologic Failure All regimens included 2 NRTIs Source: Cohen C, et al. 17 th International AIDS Conference. 2010:THLBB206.
36 Investigational Rilpivirine (TMC-278) vs. Efavirenz in ARV-Naive ECHO and THRIVE: Results 48 Week Data: Discontinuation Due to Adverse Effects All regimens included 2 NRTIs Source: Cohen C, et al. 17 th International AIDS Conference. 2010:THLBB206.
37 Summary and Implications Rilpivirine ECHO and Thrive Studies Overall similar results as efavirenz Well-tolerated, convenient NNRTI Unexpected higher virologic failure rate than with efavirenz
38 RPV/TDF/FTC Indications [1] RPV/TDF/FTC DHHS guidelines 2013 [2] RPV is not recommended in patients with pretreatment HIV-1 RNA > 100,000 copies/ml Higher rate of virologic failures reported in patients with pre-art CD4+ count < 200 cells/mm 3 who were treated with RPV + 2 NRTIs 1. RPV/TDF/FTC [package insert]. June DHHS Guidelines. February 2013.
39 What s Available as Fixed-Dose Combinations, and What s Coming? Available Now Efavirenz/tenofovir DF/ emtricitabine Rilpivirine/tenofovir DF/ emtricitabine Elvitegravir/cobicistat/ tenofovir DF/emtricitabine Future Options Darunavir/cobicistat Darunavir/cobicistat/ emtricitabine/tenofovir alafenamide (GS-7340) Atazanavir/cobicistat Dolutegravir/abacavir/ lamivudine Dolutegravir will be initially available as single tablet, not fixed-dose combination
40 Quad Pill Tenofovir + Emtricitabine + Cobicistat + Elvitegravir Booster INSTI
41 Cobicistat: A New Boosting Agent Small molecule with no HIV activity No concern of drug resistance in pts with suboptimal virologic response Similar from BL in fasting TC and TGs compared with RTV when boosting same agent [1] Inhibitor of CYP3A4; many drug drug interactions [2,3] Modest, rapid increase in serum Cr due to inhibition of tubular secretion [3] Not associated with any change in actual GFR Other drugs (including ARVs) have similar effect [4,5] Availability of cobicistat has allowed for development of new coformulated agents and regimens 1. Gallant JE, et al. J Infect Dis. 2013;208: DHHS Guidelines February TDF/FTC/EVG/COBI [package insert]. 4. RPV [package insert]. 5. DTG [package insert].
42 Study 102: QUAD Versus Efavirenz/Emtricitabine/Tenofovir DF Single-Tablet, Once-Daily Regimens Phase 3 study (192 weeks) Treatment-naïve Double-blind HIV RNA >5000 copies/ml Any CD4 count Non-inferiority (12% margin) Randomization 1:1 Elvitegravir 150 mg/cobicistat 150 mg/ Emtricitabine/Tenofovir DF (n=348) Efavirenz 600 mg/ Emtricitabine/Tenofovir DF (n=352) Primary Endpoint Week 48 HIV RNA <50 Copies/mL Sax PE, et al. Lancet. 2012;379: Zolopa A, et al. J Int AIDS Soc. 2012;15(suppl 4): Abstract O424a.
43 Patients (%) CD4 Gain (cells/mm 3 ) Study 102: Virologic and Immunologic Outcomes HIV RNA <50 Copies/mL CD4 Cell Gain EVG/COBI/FTC/TDF EFV/FTC/TDF EVG/COBI/FTC/TDF EFV/FTC/TDF Difference (%): 3.6 (-1.6, 8.8) 88% 84% Difference (%): 2.7 (-2.9, 8.3) 84% 82% 239* (n=348/352) Week 96 (n=348/352) *P= (n=325/315) Week Sax PE, et al. Lancet. 2012;379: Zolopa A, et al. J Int AIDS Soc. 2012;15(suppl 4): Abstract O424a. 96 (n=307/302)
44 Patients (%) Patients (%) Study 102: Virologic Outcomes by Baseline HIV RNA Baseline HIV RNA <100K Copies/mL Baseline HIV RNA >100K Copies/mL EVG/COBI/FTC/TDF EFV/FTC/TDF EVG/COBI/FTC/TDF EFV/FTC/TDF 90% 85% 86% 81% 84% 82% 81% 83% 48 (n=348/352) Week 96 (n=230/236) Sax PE, et al. Lancet. 2012;379: Zolopa A, et al. J Int AIDS Soc. 2012;15(suppl 4): Abstract O424a. 48 (n=348/352) Week 96 (n=230/236)
45 Study 103: QUAD Versus Atazanavir/r + Emtricitabine/Tenofovir DF Once-Daily Regimens Phase 3 study (192 weeks) Treatment-naïve Double-blind HIV RNA >5000 copies/ml Any CD4 count Non-inferiority (12% margin) Randomization 1:1 Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF (n=353) Atazanavir/r + Emtricitabine/Tenofovir DF (n=355) Primary Endpoint Week 48 HIV RNA <50 Copies/mL DeJesus E, et al. Lancet. 2012;379: Rockstroh J, et al. J Int AIDS Soc. 2012;15(suppl 4): Abstract O424b.
46 Elvitegravir/Cobicistat vs EFV or ATV/RTV + TDF/FTC in Treatment-Naive Pts Randomized, double-blind, active-controlled phase III studies Primary endpoint: HIV-1 RNA < 50 copies/ml at Wk 48 Study 102 [1] (N = 700) Treatment naive HIV-1 RNA 5000 copies/ml Any CD4+ cell count Susceptible to TDF, FTC, and EFV, or ATV egfr 70 ml/min Study 103 [2] (N = 708) EVG/COBI/TDF/FTC QD (n = 348) EFV/FTC/TDF QD (n = 352) EVG/COBI/TDF/FTC QD (n = 353) ATV/RTV + TDF/FTC QD (n = 355) 1. Sax P, et al. Lancet. 2012;379: DeJesus E, et al. Lancet. 2012;379:
47 Patients (%) EVG/COBI/TDF/FTC Noninferior to EFV/TDF/FTC Through Wk EVG/COBI/TDF/FTC (n = 348) EFV/TDF/FTC (n = 352) 95% CI for Difference Favors EFV Favors EVG/COBI Wk Wk Wk Wk Wk Wk Wk Wk Wk Virologic Success* Virologic Failure No Data *HIV-1 RNA < 50 c/ml as defined by FDA Snapshot algorithm. Discontinued for AE, death, or missing data. Wk 48 [1] Wk 96 [2] Wk 144 [3] 3.6% -1.6% 2.7% -2.9% 4.9% 8.8% -1.3% 11.1% -12% 12% 0 1. Sax PE, et al. Lancet. 2012;379: Zolopa A, et al. J Acquir Immune Defic Syndr. 2013;63: Wohl D, et al. ICAAC Abstract H-672a. Graphic reproduced with permission.
48 Considerations for Patients Without Other Medical Concerns Adherence Patient preference (ie, simple regimen) Efficacy Baseline HIV-1 RNA > 100,000 copies/ml Use abacavir with caution Rilpivirine not recommended Concerns about specific adverse events
49 Switch Strategy
50 Mean Concentration (ng/ml) Switching From EFV/TDF/FTC to RPV/TDF/FTC in Suppressed Patients Single-arm study of 50 patients virologically suppressed on EFV/TDF/FTC as first regimen for 3 mos No known resistance mutations to study meds Desiring to switch for intolerance of regimen 100% maintained HIV-1 RNA < 50 c/ml at Wk 12 after switch to RPV/TDF/FTC (primary endpoint) No events leading to discontinuation after switch RPV mean C trough within target range by 2 wks Plasma Concentrations of RPV (C trough ) or EFV (Any Time) EFV concentration RPV C trough RPV mean C trough in ECHO/THRIVE Mills A, et al. ICAAC Abstract H2-794c. Wks After Switch
51 TAF (tenofovir alafenamide)
52 48-Wk Results of TAF vs Tenofovir DF in ART- Naive Pts TAF (GS-7340), investigational prodrug of tenofovir with lower TFV plasma concentrations, increased delivery to hepatocytes, lymphoid cells Randomized, placebo-controlled, phase II trial of TAF vs TDF, each coformulated with FTC/EVG/COBI, in ART-naive patients Gut TFV TDF TAF Plasma TDF/TFV TAF Lymphoid Cells TAF Cathepsin A TFV TFV-MP ART-naive patients, CD4+ cell count > 50 cells/mm 3, egfr 70 ml/min (N = 170) Wk 24 TAF/FTC/EVG/COBI (n = 112) TDF/FTC/EVG/COBI (n = 58) Wk 48 TFV-DP Zolopa A, et al. CROI Abstract 99LB. Sax P, et al. ICAAC Abstract H-1464d. Reproduced with permission.
53 Patients (%) TAF/FTC/EVG/COBI Noninferior to TDF/FTC/EVG/COBI Through Wk Δ 1.0% (95% CI: to +10.0; P =.84) n = Virologic Success* 6.3 TAF/FTC/EVG/COBI TDF/FTC/EVG/COBI Virologic Nonresponse No Data *HIV-1 RNA < 50 c/ml as defined by FDA Snapshot algorithm. Discontinued for AE, death, or missing data. Noninferiority at Wk 24 primary endpoint analysis [1] 89.7% vs 87.5 % with HIV- 1 RNA < 50 c/ml, respectively 6 pts (3 per arm) eligible for resistance analysis at Wk 48 [2] No pts with resistance in TAF arm 1 pt with NRTI and INSTI resistance in TDF arm (M184V, E92Q) 1. Zolopa A, et al. CROI Abstract 99LB. 2. Sax P, et al. ICAAC Abstract H-1464d.
54 Median (Q1, Q3) Change in BMD Median (Q1, Q0) Change in BMD Change in egfr and BMD With TAF vs TDF at Wk 48 Patients on TAF had smaller decrease in egfr 2 TAF/FTC/EVG/COBI (n = 112) TDF/DTC/EVG/COBI (n = 58) -5.5 vs ml/min with TDF (P =.041) No renal discontinuations and no tubulopathy in either arm Less change in renal tubular proteins with TAF Spine P <.001 Smaller change in both spine and hip BMD (by DXA) over 48 wks with TAF vs TDF Sax P, et al. ICAAC Abstract H-1464d. Reproduced with permission Hip Wks P <.001
55 HIV Entry DHS/P P
56
57 CD4 Co-receptors: CCR5 and CXCR4
58 Clinical Trials Tx-naïve (MERIT Trial) Tx-experience (MOTIVATE I-II)
59 FDA Approves First Drug for Reducing the Risk of Sexually Acquired HIV Infection (July 16, 2012) Available at:
60 CDC Interim Guidance for Healthcare Providers: Beginning PrEP Medication Regimen Prescribe emtricitabine/tenofovir DF (200/300 mg) 1 tablet daily In general, prescribe no more than a 90-day supply Renew only after confirming patient remains HIV uninfected If HBV infected Consider emtricitabine/tenofovir DF for HBV and HIV prevention Provide risk-reduction and PrEP medication adherence counseling and condoms CDC. MMWR Morb Mortal Wkly Rep. 2011;60: CDC. MMWR Morb Mortal Wkly Rep. 2012;61:
61 CDC Interim Guidance for Healthcare Providers: Follow-Up While on PrEP Evaluate and support PrEP medication adherence at each follow-up visit (more often if needed) For women, conduct pregnancy test Every 2 to 3 months HIV antibody test (document negative result) Assess Risk behaviors and provide risk-reduction counseling and condoms STI symptoms (if present, test and treat as needed) Every 6 months Test for STI regardless of symptomatology (treat as needed) Every 3 months after initiation, then yearly while on PrEP Blood urea nitrogen Serum creatinine CDC. MMWR Morb Mortal Wkly Rep. 2011;60: CDC. MMWR Morb Mortal Wkly Rep. 2012;61:
62 Conclusions Currently many simple and easy-to-administer Co-formulations of first-line antiretroviral regimens The decision as to which regimen to select first is based upon efficacy, safety, Cost, and select characteristics Adherence Virologic characteristic (eg, baseline HIV-1 RNA, drug resistance) Comorbid conditions Cobicistat new pharmacologic booster Effective in increasing exposure of these drugs with no HIV activity However, effects on serum creatinine and need for renal monitoring important for use with this drug
Antiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationL infettivologia del 3 millennio: AIDS ed altro
L infettivologia del 3 millennio: AIDS ed altro VI Convegno Nazionale 15-16 -17 maggio 2014 Centro Congressi Hotel Ariston Paestum (SA) Nuove molecole ad azione anti-hiv Annalisa Saracino Clinica Malattie
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationART: The New, The Old and The Ugly
ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationHIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD
HIV Update On The Cutting Edge A Chronic Disease Rhett M Shirley, MD CDC Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics,
More informationCROI 2013: New Drugs for Treatment and PrEP
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationQué anuncian los nuevos trials?
Qué anuncian los nuevos trials? XVII Curso Nacional VIH/SIDA Sociedad Chilena de Infectología Agosto 2014 Dr. Carlos Beltrán Hospital Barros Luco Trudeau Universidad de Santiago Grupo SidaChile El presente
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationIntegrase Inhibitors in the Treatment HIV-Infection. Andrew Zolopa, MD Stanford University
Integrase Inhibitors in the Treatment HIV-Infection Andrew Zolopa, MD Stanford University 1 IAS-USA 212 Guidelines Updated Recommendations When to start ART is now recommended for all patients, regardless
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationTenofovir Alafenamide (TAF)
Frontier AIDS Education and Training Center Tenofovir Alafenamide (TAF) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO January 28, 2016
More informationAntiretroviral Treatment 2014
Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon
More informationHIV: Approach to the Treatment-Naïve Patient
HIV: Approach to the Treatment-Naïve Patient Paul E. Sax, M.D. Clinical Director, Division of Infectious Diseases Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Approach
More informationAntiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies. Joel Gallant, MD, MPH Johns Hopkins University School of Medicine
Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies Joel Gallant, MD, MPH Johns Hopkins University School of Medicine Initial Regimen: DHHS Guidelines 3/27/2012 Preferred Regimens
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More information2017 NSTC Annual Meeting Eric Daar April 18, 2017
Antiretroviral Therapy Update for TB Clinicians Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grants Consultant
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationAntiretroviral Treatment: What's in the Pipeline
Antiretroviral Treatment: What's in the Pipeline Joseph P. McGowan, MD, FACP, FIDSA Professor of Medicine Hofstra North Shore-LIJ School of Medicine October 14, 2015 Which describes best how HIV Maturation
More information2/16/2017. Management and Prevention of HIV Infection: Case Discussion. Case 1. Case 1
Management and Prevention of HIV Infection: Case Discussion Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grant
More informationTUESDAY AM HIV DISCUSSION SERIES. 8/25/2015 Management of Treatment-Naïve Patients Ellen Kitchell, M.D.
TUESDAY AM HIV DISCUSSION SERIES 8/25/2015 Management of Treatment-Naïve Patients Ellen Kitchell, M.D. HAART Initiation/HIV Treatment for Antiretroviral-Naïve Patients Ellen Kitchell, M.D. The Art of HAART
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationCROI 2018 Report Back
CROI 2018 Report Back Monika Roy, MD MAS Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine bayareaaetc.org 1 Disclosures and Conflicts of Interest Nothing to report bayareaaetc.org
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationTerapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales
Terapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales clinicaloptions.com/hiv Eficacia en Ensayos Clínicos pivotales
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationHighlights of AIDS 2012 CCO Official Conference Coverage of the XIX International AIDS Conference
Highlights of AIDS 2012 CCO Official Conference Coverage of the XIX International AIDS Conference July 22-27, 2012 Washington, DC Sylvia Ojoo, MRCP UK Clinical Assistant Professor of Medicine University
More informationStarting and Switching ART: 2016
Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,
More informationTim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC
Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pipeline is robust! Several drugs, coformulations,
More informationAbstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo
WEEK 8 RESULTS OF AMBER: A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL IN ANTIRETROVIRAL TREATMENT (ART)-NAÏVE HIV--INFECTED ADULTS TO EVALUATE THE EFFICACY AND SAFETY OF THE ONCE-DAILY, SINGLE-TABLET REGIMEN
More informationHAART Initiation/HIV Treatment for Antiretroviral-Naïve Patients. Ellen Kitchell, M.D.
HAART Initiation/HIV Treatment for Antiretroviral-Naïve Patients Ellen Kitchell, M.D. A Smorgasbord of Possibilities Picking Out A Delicious Meal For Your Patient There are many fantastic options currently
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationWhat next? Francois Venter. ART new drugs, new studies. Wits Reproductive Health & HIV Institute
Thanks: Polly Clayden, Francesca Conradie, Loyd Mulenga, Gary Maartens, Andrew Hill, David Ripin, Elli Katabira, Chris Duncombe, Nathan Ford, Marco Vitoria, WHO Industry: Gilead, Janssen, ViivV Abbott,
More informationStribild, a Single Tablet Regimen for the Treatment of HIV Disease
Comb Prod Ther (2013) 3:1 8 DOI 10.1007/s13556-013-0001-y REVIEW Stribild, a Single Tablet Regimen for the Treatment of HIV Disease Cynthia Brinson To view enhanced content go to www.combitherapy-open.com
More informationResistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
Viruses 2014, 6, 2858-2879; doi:10.3390/v6072858 Review OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical
More informationGS-1489: STUDY DESIGN
A PHASE 3 RANDOMIZED CONTROLLED CLINICAL TRIAL OF BICTEGRAVIR IN A FIXED DOSE COMBINATION,, VS ABC/DTG/3TC IN TREATMENT-NAÏVE ADULTS AT WEEK 48 J. Gallant, A. Lazzarin, A. Mills, C. Orkin, D. Podzamczer,
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationUnderstanding the unmet medical needs with current ART
Thanks: Polly Clayden, Francesca Conradie, Loyd Mulenga, Gary Maartens, Andrew Hill, David Ripin, Elli Katabira, Chris Duncombe, Nathan Ford, Marco Vitoria, WHO, Trip Gullik Industry: Gilead, Janssen,
More informationAntiretroviral Therapy: When and What to Start. Joe Eron, MD University of North Carolina at Chapel Hill School of Medicine
Antiretroviral Therapy: When and What to Start Joe Eron, MD University of North Carolina at Chapel Hill School of Medicine Learning Objectives As a results of participating in this activity participants
More informationDrug toxicities: Safest PIs. Michelle Moorhouse 14 Apr 2016
Drug toxicities: Safest PIs Michelle Moorhouse 14 Apr 2016 Impact of PIs on AIDS mortality CDC.gov. Epidemiology of HIV infection. Evolution of PIs http://www.clinicaloptions.com/hiv/treatment%20updates/boosted%20pis/interactive%20virtual%20presentation/slideset.aspx
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationSingle Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era
Activity Code FM285 Single Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era Monica Gandhi MD, MPH Clinic Director, Ward 86 HIV Clinic, SFGH/UCSF Learning Objectives Upon
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationFirst-Line Antiretroviral Therapy for Treatment and Prevention:
First-Line Antiretroviral Therapy for Treatment and Prevention: The Past, Present and Future Best Options Joel Gallant, MD, MPH Johns Hopkins University School of Medicine IAS-USA Guidelines 7/2008: When
More informationCROI 2012 New Frontiers. TM Rossouw
CROI 2012 New Frontiers TM Rossouw Outline When to start? What to start with? Any new drugs? Long-term complications Prevention Basic science When to Start? Drug toxicity Preservation of limited Rx options
More informationThe Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases
De afbeelding kan niet worden weergegeven. The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases DISCLOSURE
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationDavid Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone
David Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone 423-439-6245 Email cluckd@etsu.edu Recall newly approved antiretrovirals and their respective place in therapy
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationHIV Treatment Update 8/3/2015. When to Start. Disclosures
8/3/215 HIV Treatment Update Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationTreatment update. Bronagh McBrien June 2016
Treatment update Bronagh McBrien June 2016 Speaker Name Bronagh McBrien Statement Received educational funding and support from Gilead, Merck, Boehringer Ingelheim, Janssen-Cilag Date : 27 June 2016 BHIVA
More informationDolutegravir: Pros and Cons (Are There Any Cons?)
Mountain West AIDS Education and Training Center Dolutegravir: Pros and Cons (Are There Any Cons?) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, MW AETC
More informationAntiretroviral Therapy in Joel Gallant, MD, MPH Johns Hopkins University School of Medicine
Antiretroviral Therapy in 2013 Joel Gallant, MD, MPH Johns Hopkins University School of Medicine When to Start When to Start: DHHS Guidelines, February 2013 ART recommended for all HIV+ individuals to
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationART Treatment. ART Treatment
Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More information1/13/16. Updated April 2015
Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP Assistant Professor UNM College of Pharmacy bjakeman@salud.unm.edu Pharmacist objectives: 1. Summarize key updates to the DHHS treatment guidelines. 2. Identify
More informationSimplifying Antiretroviral Therapy Regimens: It s not so simple
Simplifying Antiretroviral Therapy Regimens: It s not so simple Jonathan Colasanti, MD, MSPH Division of Infectious Diseases Emory University School of Medicine Disclosures No Financial Disclosures Parts
More informationBHIVA antiretroviral treatment guidelines 2015
BHIVA antiretroviral treatment guidelines 2015 Duncan Churchill Brighton & Sussex University Hospitals NHS Trust Laura Waters Mortimer Market Centre, CNWL Duncan Churchill GENERAL POINTS & WHEN TO START
More informationAdvances in HIV Treatment: When to Start Treatment Which Antivirals to Use
Advances in HIV Treatment: When to Start Treatment Which Antivirals to Use Calvin Cohen MD Harvard Vanguard Medical Associates CRI New England Vice Chair, Science Steering Cmte, INSIGHT Boston MA Learning
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationOptimizing ARV For Women
Optimizing ARV For Women Kathleen E. Squires, MD W Paul and Ida H Havens Professor of Infectious Diseases Director, Division of Infectious Diseases Sidney Kimmel Medical College of Thomas Jefferson University
More informationWHEN TO START? CROI 2015: Focus on ART
CROI 215: Focus on ART FORMATTED: 4-1-15 Washington, DC: May 13, 215 Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine Chief, Division of Infectious Diseases Weill Cornell Medical
More informationEvolving HIV Treatment Paradigms What we need to know
Evolving HIV Treatment Paradigms What we need to know Benjamin Young International Association of Providers of AIDS Care Washington, DC, USA Evolving HIV Treatment Paradigms When/who to treat Better medicines
More informationCOMPETING INTEREST OF FINANCIAL VALUE
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Ian Williams University College London Medical School COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Ian Williams
More informationAntiretroviral Therapy: Panel Discussion
disclosures Antiretroviral Therapy: Panel Discussion Medical Management of HIV December 9, 217 Panelists: Harry Lampiris, MD; Annie Luetkemeyer, MD; Carina Marquez, MD Moderator: Oliver Bacon, MD none
More information